Liver involvement in pediatric rheumatic diseases

SUN Fei, MAO Huawei

PDF(591 KB)
PDF(591 KB)
Journal of Clinical Hepatol ›› 2025, Vol. 41 ›› Issue (05) : 823-827. DOI: 10.12449/JCH250505
Expert Forum

Liver involvement in pediatric rheumatic diseases

Author information +
History +

Abstract

Pediatric rheumatic diseases are a group of complex chronic inflammatory disorders，mainly including juvenile idiopathic arthritis，diffuse connective tissue diseases，systemic vasculitis，and autoinflammatory diseases. Liver involvement is quite common in pediatric rheumatic diseases. In most cases，pediatric rheumatic diseases with liver involvement manifest as varying degrees of abnormal liver enzymes or hepatomegaly and may not have significant liver parenchyma lesions，and such diseases rarely progress to liver decompensation. Only a few children with rheumatic diseases may develop severe liver lesions. Liver involvement in children with rheumatic diseases may be caused by the primary disease itself or concurrent autoimmune liver diseases，but secondary factors are more common，including drug-induced liver damage caused by drugs used to treat rheumatic diseases，viral hepatitis，and fatty liver disease. This article summarizes liver involvement in pediatric rheumatic diseases，in order to provide a reference for the etiological analysis，diagnosis，and treatment strategies of liver involvement in pediatric rheumatic diseases.

Key words

Rheumatic Diseases / Liver Involvement / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
SUN Fei , MAO Huawei. Liver involvement in pediatric rheumatic diseases. Journal of Clinical Hepatol. 2025, 41(05): 823-827 https://doi.org/10.12449/JCH250505

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
[1]
SCHALLER J, BECKWITH B, WEDGWOOD RJ. Hepatic involvement in juvenile rheumatoid arthritis[J]. 1970, 77(2): 203-210. DOI: 10.1016/s0022-3476(70)80324-9.
本文引用 [1]
[2]
GIRALDO WAS, MORATILLA AB, CAPARRÓS AM, et al. Nodular regenerative hyperplasia of the liver as a complication of long-standing systemic-onset juvenile idiopathic arthritis[J]. Reumatol Clin, 2014, 10(3): 194-195. DOI: 10.1016/j.reuma.2013.09.001.
本文引用 [1]
[3]
CANNA S, FRANKOVICH J, HIGGINS G, et al. Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist[J]. Pediatr Rheumatol Online J, 2009, 7: 21. DOI: 10.1186/1546-0096-7-21.
本文引用 [1]
[4]
RUPERTO N, BRUNNER HI, QUARTIER P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis[J]. N Engl J Med, 2012, 367(25): 2396-2406. DOI: 10.1056/NEJMoa1205099.
本文引用 [1]
[5]
GENOVESE MC, KREMER JM, van VOLLENHOVEN RF, et al. Transaminase levels and hepatic events during tocilizumab treatment: Pooled analysis of long-term clinical trial safety data in rheumatoid arthritis[J]. Arthritis Rheumatol, 2017, 69(9): 1751-1761. DOI: 10.1002/art.40176.
本文引用 [1]
[6]
MINOIA F, DAVÌ S, HORNE A, et al. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A multinational, multicenter study of 362 patients[J]. Arthritis Rheumatol, 2014, 66(11): 3160-3169. DOI: 10.1002/art.38802.
本文引用 [1]
[7]
FAUTREL B, MITROVIC S, DE MATTEIS A, et al. EULAR/PReS recommendations for the diagnosis and management of Still’s disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still’s disease[J]. Ann Rheum Dis, 2024, 83(12): 1614-1627. DOI: 10.1136/ard-2024-225851.
本文引用 [1]
[8]
IRVING KS, SEN D, TAHIR H, et al. A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus-a retrospective review of cases[J]. Rheumatology (Oxford), 2007, 46(7): 1171-1173. DOI: 10.1093/rheumatology/kem108.
本文引用 [3]
[9]
TAKAHASHI A, ABE K, SAITO R, et al. Liver dysfunction in patients with systemic lupus erythematosus[J]. Intern Med, 2013, 52(13): 1461-1465. DOI: 10.2169/internalmedicine.52.9458.
[10]
TAHERNIA L, ALIMADADI H, TAHGHIGHI F, et al. Frequency and type of hepatic and gastrointestinal involvement in juvenile systemic lupus erythematosus[J]. Autoimmune Dis, 2017, 2017: 8097273. DOI: 10.1155/2017/8097273.
本文引用 [1]
[11]
PIGA M, VACCA A, PORRU G, et al. Liver involvement in systemic lupus erythematosus: Incidence, clinical course and outcome of lupus hepatitis[J]. Clin Exp Rheumatol, 2010, 28(4): 504-510.
本文引用 [1]
[12]
TRAPANI S, RUBINO C, SIMONINI G, et al. Gastrointestinal and hepatic involvement in paediatric systemic lupus erythematosus[J]. Clin Exp Rheumatol, 2021, 39(4): 899-906. DOI: 10.55563/clinexprheumatol/oebrcq.
本文引用 [3]
[13]
EL-SHABRAWI MH, FARRAG MI. Hepatic manifestations in juvenile systemic lupus erythematosus[J]. Recent Pat Inflamm Allergy Drug Discov, 2014, 8(1): 36-40. DOI: 10.2174/1872213x07666131229110501.
本文引用 [1]
[14]
AFZAL W, HAGHI M, HASNI SA, et al. Lupus hepatitis, more than just elevated liver enzymes[J]. Scand J Rheumatol, 2020, 49(6): 427-433. DOI: 10.1080/03009742.2020.1744712.
本文引用 [1]
[15]
ADIGA A, NUGENT K. Lupus hepatitis and autoimmune hepatitis (lupoid hepatitis)[J]. Am J Med Sci, 2017, 353(4): 329-335. DOI: 10.1016/j.amjms.2016.10.014.
本文引用 [1]
[16]
DEEN MJ, PORTA G, FIOROT FJ, et al. Autoimmune hepatitis and juvenile systemic lupus erythematosus[J]. Lupus, 2009, 18(8): 747-751. DOI: 10.1177/0961203308100559.
本文引用 [1]
[17]
BALBI VA, MONTENEGRO B, PITTA AC, et al. Autoimmune hepatitis in 847 childhood-onset systemic lupus erythematosus population: A multicentric cohort study[J]. Adv Rheumatol, 2018, 58(1): 43. DOI: 10.1186/s42358-018-0043-7.
本文引用 [1]
[18]
PAWŁOWSKA J, NAORNIAKOWSKA M, LIBER A. Liver involvement in children with collagen vascular diseases[J]. Clin Exp Hepatol, 2015, 1(3): 117-119. DOI: 10.5114/ceh.2015.55569.
本文引用 [1]
[19]
GRYKA-MARTON M, SZUKIEWICZ D, TELIGA-CZAJKOWSKA J, et al. An overview of neonatal lupus with anti-ro characteristics[J]. Int J Mol Sci, 2021, 22(17): 9281. DOI: 10.3390/ijms22179281.
本文引用 [1]
[20]
DERDULSKA JM, RUDNICKA L, SZYKUT-BADACZEWSKA A, et al. Neonatal lupus erythematosus-practical guidelines[J]. J Perinat Med, 2021, 49(5): 529-538. DOI: 10.1515/jpm-2020-0543.
本文引用 [1]
[21]
RUSSO RA, KATSICAS MM, DÁVILA M, et al. Cholestasis in juvenile dermatomyositis: Report of three cases[J]. Arthritis Rheum, 2001, 44(5): 1139-1142.
本文引用 [1]
[22]
KINKOR M, HAMEED S, KATS A, et al. 14-month-old female with anti-MDA5 juvenile dermatomyositis complicated by liver disease: A case report[J]. Pediatr Rheumatol Online J, 2024, 22(1): 86. DOI: 10.1186/s12969-024-01021-y.
本文引用 [1]
[23]
YI BY, MARRS J, SCHENKER R, et al. Elevated liver enzymes: Unusual presentation of anti-MDA5 antibody-associated juvenile dermatomyositis[J]. Clin Exp Rheumatol, 2024, 42(2): 456-457. DOI: 10.55563/clinexprheumatol/25znui.
本文引用 [1]
[24]
RAMOS-CASALS M, ACAR-DENIZLI N, VISSINK A, et al. Childhood-onset of primary Sjögren’s syndrome: Phenotypic characterization at diagnosis of 158 children[J]. Rheumatology (Oxford), 2021, 60(10): 4558-4567. DOI: 10.1093/rheumatology/keab032.
本文引用 [1]
[25]
GONG YN, LIU HM, LI GM, et al. Childhood-onset primary Sjögren’s syndrome in a tertiary center in China: Clinical features and outcome[J]. Pediatr Rheumatol Online J, 2023, 21(1): 11. DOI: 10.1186/s12969-022-00779-3.
本文引用 [1]
[26]
MARINO A, ROMANO M, GIANI T, et al. Childhood Sjogren’s syndrome: An Italian case series and a literature review-based cohort[J]. Semin Arthritis Rheum, 2021, 51(4): 903-910. DOI: 10.1016/j.semarthrit.2020.11.004.
[27]
KASHIWAGI Y, HATSUSHIKA T, TSUTSUMI N, et al. Gastrointestinal and liver lesions in primary childhood Sjögren syndrome[J]. Clin Rheumatol, 2017, 36(6): 1433-1435. DOI: 10.1007/s10067-017-3599-4.
本文引用 [1]
[28]
GEBRESELASSIE A, ADULI F, HOWELL CD. Rheumatologic diseases and the liver[J]. Clin Liver Dis, 2019, 23(2): 247-261. DOI: 10.1016/j.cld.2018.12.007.
本文引用 [1]
[29]
CHAO HC, KONG MS, LIN SJ. Hepatobiliary involvement of Henoch-Schönlein purpura in children[J]. Acta Paediatr Taiwan, 2000, 41(2): 63-68.
本文引用 [1]
[30]
GATSELIS NK, STEFOS A, GIOTI C, et al. Primary biliary cirrhosis and Henoch-Schonlein purpura: Report of two cases and review of the literature[J]. Liver Int, 2007, 27(2): 280-283. DOI: 10.1111/j.1478-3231.2006.01402.x.
本文引用 [1]
[31]
REN YF, ZHANG CX, XU XQ, et al. A case report of atypical Kawasaki disease presented with severe elevated transaminases and literature review[J]. BMC Infect Dis, 2021, 21(1): 415. DOI: 10.1186/s12879-021-06101-y.
本文引用 [2]
[32]
MORITA A, IMAGAWA K, ISHIODORI T, et al. Kawasaki disease with dilatation of the common bile duct: A case report and review of literature[J]. Int J Rheum Dis, 2021, 24(10): 1325-1330. DOI: 10.1111/1756-185X.14208.
本文引用 [1]
[33]
PRATAP K, GARDNER LS, GILLIS D, et al. Hepatic predominant presentation of Kawasaki disease in adolescence case report and review of literature[J]. BMC Gastroenterol, 2020, 20(1): 352. DOI: 10.1186/s12876-020-01461-2.
本文引用 [1]
[34]
UNAL F, CAKIR M, BARAN M, et al. Liver involvement in children with familial Mediterranean fever[J]. Dig Liver Dis, 2012, 44(8): 689-693. DOI: 10.1016/j.dld.2012.01.003.
本文引用 [1]
[35]
BAYRAMOGLU Z, AKYOL SARI ZN, KOKER O, et al. Shear wave elastography evaluation of liver, pancreas, spleen and kidneys in patients with familial mediterranean fever and amyloidosis[J]. Br J Radiol, 2021, 94(1128): 20210237. DOI: 10.1259/bjr.20210237.
本文引用 [1]
[36]
FRAISSE T, SAVEY L, HENTGEN V, et al. Non-amyloid liver involvement in familial Mediterranean fever: A systematic literature review[J]. Liver Int, 2020, 40(6): 1269-1277. DOI: 10.1111/liv.14445.
本文引用 [1]
[37]
AOKI M, IZAWA K, TANAKA T, et al. Case report: A pediatric case of familial Mediterranean fever concurrent with autoimmune hepatitis[J]. Front Immunol, 2022, 13: 917398. DOI: 10.3389/fimmu.2022.917398.
本文引用 [1]
[38]
WANG W, WANG W, ZOU LP, et al. Clinical characteristics of 25 patients with type I interferonopathies[J]. Chin J Pediatr, 2021, 59(12): 1043-1047. DOI: 10.3760/cma.j.cn112140-20211004-00843.
王伟, 王薇, 邹丽萍, 等. Ⅰ型干扰素病25例临床特点分析[J]. 中华儿科杂志, 2021, 59(12): 1043-1047. DOI: 10.3760/cma.j.cn112140-20211004-00843.
本文引用 [1]
[39]
GAVAZZI F, CROSS ZM, WOIDILL S, et al. Hepatic involvement in aicardi-goutières syndrome[J]. Neuropediatrics, 2021, 52(6): 441-447. DOI: 10.1055/s-0040-1722673.
本文引用 [1]
[40]
ELHANI I, RILLER Q, BOURSIER G, et al. A20 haploinsufficiency: A systematic review of 177 cases[J]. J Investig Dermatol, 2024, 144(6): 1282-1294. DOI: 10.1016/j.jid.2023.12.007.
本文引用 [1]
[41]
IWASA T, MIWA TK, UNOME S, et al. A case of A20 haploinsufficiency complicated by autoimmune hepatitis[J]. Hepatol Res, 2024, 54(6): 606-611. DOI: 10.1111/hepr.14003.
本文引用 [1]
[42]
KIM HY, SONG JY, KIM WI, et al. The first case of an infant with familial A20 haploinsufficiency in Korea[J]. J Korean Med Sci, 2020, 35(30): e252. DOI: 10.3346/jkms.2020.35.e252.
本文引用 [1]
[43]
LI GM, LIU HM, GUAN WZ, et al. Expanding the spectrum of A20 haploinsufficiency in two Chinese families: Cases report[J]. BMC Med Genet, 2019, 20(1): 124. DOI: 10.1186/s12881-019-0856-1.
本文引用 [1]
[44]
DESHAYES S, BAZILLE C, KHOURI E EL, et al. Chronic hepatic involvement in the clinical spectrum of A20 haploinsufficiency[J]. Liver Int, 2021, 41(8): 1894-1900. DOI: 10.1111/liv.14935.
本文引用 [1]
[45]
JINDAL AK, PILANIA RK, SURI D, et al. A young female with early onset arthritis, uveitis, hepatic, and renal granulomas: A clinical tryst with Blau syndrome over 20 years and case-based review[J]. Rheumatol Int, 2021, 41(1): 173-181. DOI: 10.1007/s00296-019-04316-6.
本文引用 [1]
[46]
CROPLEY A, ASHRAFY AH, WELTMAN M. An original description of granulomatous liver cirrhosis in Blau syndrome[J]. Dig Dis Sci, 2019, 64(11): 3346-3349. DOI: 10.1007/s10620-019-05682-8.
本文引用 [1]

孙菲负责资料分析，收集数据，撰写论文；毛华伟负责课题设计，拟定写作思路，指导撰写文章并最后定稿。

Funding

National Key R&D Program of China(2021YFC2702005)
Beijing Hospitals Authority Clinical Medicine Development of Special Funding(ZLRK202527)
Beijing Hospitals Authority’s Ascent Plan(DFL20221001)

Comments

PDF(591 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Clinical Hepatol, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉